Articles tagged with Antibodies
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
Researchers at Max Planck Institute of Molecular Physiology discovered that vaccination after COVID-19 recovery increases neutralizing antibody levels by up to five times, providing better protection against current coronavirus variants. The study involved 140 volunteers and showed that antibody levels remained high even after 300 days.
Children previously infected with COVID-19 develop long-lasting natural circulating antibodies that provide immunity. The study's findings suggest that these antibodies can last for at least seven months and do not differ by age, weight, or severity of symptoms.
A new study found that follicular T cells help balance out antibody diversity and affinity after COVID-19 vaccination. Deleting specific cell types altered the immune response, providing insights into strategies to enhance vaccine effectiveness later in life.
A study compared the antibody response in human milk after vaccination with four COVID-19 vaccines, revealing differences in immune system activation. The findings provide valuable insights into vaccine effectiveness and potential impact on infant health.
A new Moffitt Cancer Center study estimates that the actual number of COVID-19 infections in Hillsborough County was twofold higher than reported positive tests. The study, conducted between October 2020 and March 2021, found nearly 100% of persons who had confirmed or suspected infection were antibody-positive.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
The new laboratory will use microfluidics, AI, and machine learning to conduct thousands of parallel experiments on single-cell eukaryotic yeast and other microbes. This will simplify the study of biology and provide a pathbreaking 'robot scientist' for fundamental research.
Research reveals SARS-CoV-2 can have multiple variants in one person, with some hiding in specific cells like kidneys or spleens. This can make complete virus clearance more difficult, as the body struggles to defend against dominant strains.
A new study by University of Bonn researchers found that cow's milk protein casein triggers an autoimmune response in mice, damaging neurons and myelin sheath. This cross-reactivity can occur when the immune system mistakes similar molecules for each other.
Researchers developed a mathematical model to predict how antibodies generated by COVID-19 vaccines confer protection against symptomatic infections. The study found that vaccine efficacy is linked to the level of neutralization titre and could enable testing of future vaccines before clinical trials.
Researchers have discovered that bioprosthetic heart valve patients develop an immune response against foreign sugars in the valves, leading to calcification and deterioration. By genetically engineering these sugars out of the valves, durability can be increased, offering a potential solution for patients.
A new study from Oregon Health & Science University found that people infected with SARS-CoV-2 develop durable immunity against variants for at least 11 months. The research suggests that immune protection may endure long-term, potentially reducing the need for vaccine booster shots.
Aston University researchers developed an AI model that can estimate daily Covid transmission rates using data from antibody tests in blood donors. The model provides a more refined view of infection rates and relative immunity compared to official measurements.
A study by MedUni Vienna found that dual-vaccinated and recovered individuals have virtually no protection against infection with the current Omicron variant of SARS-CoV-2. However, a third Corona vaccination provides partial blockade of Omicron.
A new transistor-based technology has been developed to quantify SARS-CoV-2 neutralizing antibodies in blood serum and test the efficacy of new vaccines. The device allows for fast and real-time analysis, reducing response times and costs.
Researchers have created a new type of cholera vaccine consisting of polysaccharides displayed on virus-like particles, generating long-lasting antibody responses in mice. The vaccine shows promise as a next-generation cholera vaccine, potentially replacing current vaccines that last only 2-5 years.
Researchers tracked antibody response to COVID-19 vaccination and found that antibodies improve in quality for months after vaccination. Even low levels of antibodies provide some protection as long as the virus doesn't change.
Researchers found that 90 minutes of mild-to-moderate intensity exercise after a flu or COVID-19 vaccination increased antibody production in the following four weeks. The study involved participants who exercised on a stationary bike or took a brisk walk, and similar results were seen in mice experiments.
A new US-based study published in PLOS Biology found that most people who have had COVID-19 are protected against reinfection for at least six months. The research analyzed data from 4,441 SpaceX employees and estimated an odds ratio of 0.14 to 0.28 for reinfection depending on the time period considered.
A study found that previous COVID-19 infection improves the performance of antibodies and potentially provides longer-term protection, especially in obese individuals. In contrast, vaccination does not enhance antibody quality and may not provide sustained immunity in those who have been previously infected or overweight.
A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.
A study by MedUni Vienna found that many cancer patients can build up sufficient immunity against SARS-CoV-2 after the third vaccination. However, patients with blood cancers may not develop protection due to immunosuppressive treatments.
Biologists isolated the SARS-CoV-2 nucleoprotein in its pure form to create more accurate antibody tests. The new approach significantly improves sensitivity, increasing the ability to detect antibodies to the nucleoprotein. This breakthrough helps determine if vaccinated individuals have been infected with COVID-19.
A recent study from Massachusetts General Hospital found that COVID-19 vaccination during pregnancy results in higher and more lasting antibody levels in infants. After two months, 98% of vaccinated infants had detectable IgG antibodies, while only 8% of uninfected mothers' babies did.
Children who receive repeated seasonal flu vaccines develop antibodies that provide broader protection against new strains, including pandemic viruses. This finding informs the design of a universal influenza virus vaccine for children.
Researchers developed a single-use sensor strip that can detect cerebrospinal fluid (CSF) leaks, providing a rapid diagnostic tool for patients with brain and spinal cord injuries. The test uses antibodies specific to proteins found in human CSF, detecting leaks even when other substances are present.
Researchers have characterized broadly neutralizing antibodies against the hepatitis C virus, identifying key genetic determinants of broad neutralization. These findings offer a promising basis for developing an effective vaccine against HCV.
Patients under immunosuppressive therapy have increased risk of severe COVID-19 disease courses if they don't respond to primary vaccination. A recent study found that a third booster vaccination is safe and effective in these patients, who were initially unable to produce antibodies after vaccination.
Lab tests show current anti-COVID pills remain effective against omicron, but available antibody therapies are substantially less effective. Researchers tested various treatments and found that some antibodies have lost their ability to neutralize omicron at realistic dosages.
Researchers at Kumamoto University developed a novel 'supermolecular' material that binds to protein drugs, prolongs their effect without impairing activity, and improves overall drug performance. The material, called PEG-PRX, adds polyethylene glycol chains to proteins without compromising biological action.
A new study finds that breakthrough infections following vaccination and natural infection followed by vaccination provide roughly equal levels of enhanced immune protection. Researchers at OHSU found that both groups generated greater levels of immunity compared to those who were vaccinated with no infection.
A new study reveals the Beta variant of SARS-CoV-2 can elicit a wide range of antibodies effective against both Delta and Omicron variants. The findings suggest that vaccination strategies could be improved by leveraging this broad immunity.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers found a markedly increased risk of carditis associated with BNT162b2 vaccination, particularly in adolescents after the second dose. The study's findings highlight the need for refined vaccination strategies to balance risk and benefits across different sub-populations.
Researchers at the University of Missouri identified 46 specific mutations in the Omicron variant that enable it to evade pre-existing antibodies. These mutations are particularly prevalent in the region where antibodies bind to the virus, making them a key target for future antiviral treatments.
A UK study found that over a third of care home residents and a quarter of staff in England showed evidence of SARS-CoV-2 infection during the first two waves of the pandemic. The study also revealed that antibodies against the virus became undetectable in half of the population within eight months.
Researchers discovered nine genes in S. mansoni's autophagy pathway inhibited by the primate's immune system, preventing parasite multiplication and contaminating the host. The study suggests a potential novel therapy and vaccine against schistosomiasis.
Researchers discovered that IgA and IgG antibodies regulate immune responses against endometrial cancer, improving outcomes when tumor cells express the antibody receptor pIgR. The study suggests new therapies targeting B cells or combinations with T-cell immunotherapies for enhanced efficacy.
A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.
A case series found that a fourth dose of an mRNA-based vaccine increases antispike IgG titers in kidney transplant recipients with weak serologic response after three doses. The researchers noted no safety concerns with the additional dose and suggested its use for such patients.
The study investigated the antibody response to 2 or 3 doses of the BioNTech-Pfizer vaccine in patients with solid tumors treated with anticancer agents. The researchers found that higher antibody levels were associated with better immune response and reduced risk of severe COVID-19.
A new study found that COVID-19 vaccination during pregnancy elicits high levels of antibodies in both mother and baby, regardless of when it occurs. The research suggests that pregnant women should not delay vaccination until late pregnancy, as it is likely to be beneficial for themselves and their babies.
Researchers identified antibodies targeting conserved sites on the spike protein, showing promise against future variants. Antibodies from vaccinated individuals retained some activity, while those with prior infection had reduced effectiveness.
The SARS-CoV-2 Alpha variant adapted to avoid triggering the innate immune response by increasing expression of antagonism proteins, which disable the body's first line of defense. This allows the virus to replicate under the radar in early stages of infection, significantly increasing its chances of infecting a person.
A COVID-19 antibody survey in Sierra Leone found significant underreporting of cases and low vaccination rates, posing a risk to populations with limited immunity. The study's findings call for rapid vaccine deployments and support for intellectual property waivers to address the pandemic's progression.
Despite receiving three vaccinations, kidney transplant patients have inadequate cellular and humoral protection against SARS-CoV-2, with around 90% showing little to no protection. Researchers are now investigating the efficacy and safety of a human antibody cocktail in these patients.
The Lancet infographic reviews COVID-19 diagnostic tests, highlighting their strengths and limitations. The study suggests that improved test accuracy could aid in pandemic control measures.
A new study suggests that breakthrough infections generate 'super immunity' to COVID-19, providing a robust immune response against the delta variant and potentially other variants. The study found that antibodies generated from breakthrough cases were 1,000% more effective than those from vaccinated individuals.
Researchers have discovered unique antibody-like proteins from sharks that can prevent the COVID-19 virus and its variants from infecting human cells. These shark-derived protein 'VNARs' are a promising new tool in the fight against SARS-CoV-2, with potential applications for future coronavirus outbreaks.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
Scientists have developed a fusion protein that successfully blocks replication of SARS-CoV-2 and related viruses in cell culture tests. The protein combines ACE2 with human antibody fragments, providing reliable protection against future mutations.
A study published in CMAJ found that hospital health care workers in Quebec had high seroprevalence of SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic. The highest rates were reported in hospitals with outbreaks, particularly those from older facilities.
Researchers found that a combination of natural infection and vaccination produces maximally potent antibodies against COVID-19. The study suggests that repeated exposures to the spike protein can improve the immune system's ability to produce high-quality antibodies against variants.
Researchers report that combining infection and vaccination produces high-quality antibodies effective against COVID-19 variants. The study found that prior-infected individuals who received a vaccine had potent antibodies against new variants, contrary to previous findings suggesting reduced potency.
Researchers have discovered miniature antibodies derived from llamas that can neutralize SARS-CoV-2 and its variants, including Delta and Omicron. The nanobodies' small size allows them to access hard-to-reach spots on the virus, making them a potential treatment against future variants.
A study published in Journal of Biological Rhythms found that antibody levels are higher when healthcare workers received the SARS-CoV-2 vaccine in the afternoon. The study suggests that circadian rhythms may play a role in regulating immune responses to COVID-19 vaccination.
Researchers have identified hundreds of tiny llama antibodies called nanobodies that target the SARS-CoV-2 spike protein, which current therapies do not address. Combining these nanobodies into cocktails could create potent treatments against new variants, including Omicron.
A recent study published in PLOS Pathogens found that the COVID-19 Delta variant may have a reduced ability to be neutralized by vaccines. The researchers analyzed serum samples from vaccinated individuals and found that the Delta variant was more effective at evading vaccine-induced immunity than other variants, such as Beta and Alpha.
Researchers at the University of Toronto have identified FAM72A as a crucial gene in antibody development, enabling high-quality antibodies by facilitating AID's effect. The findings also suggest that increased levels of FAM72A could spur cancer development and progression.